Unlock instant, AI-driven research and patent intelligence for your innovation.

Fusion gene ttty15‑usp9y and its application as a marker of prostate cancer

A TTTY15-USP9Y, fusion gene technology, applied in the field of molecular biology, can solve problems such as PSA elevation

Active Publication Date: 2017-06-23
SHANGHAI CHANGHAI HOSPITAL
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, PSA is a prostate-specific rather than PCa-specific molecular marker, such as prostatitis, benign prostatic hyperplasia, etc. can cause the increase of PSA
In the "diagnostic gray area" (PSA4-10ng / ml) of PSA, its diagnostic positive rate is only 25-40%, which has just caused numerous unnecessary punctures, and meanwhile, has also brought economic burden and Mental burden

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fusion gene ttty15‑usp9y and its application as a marker of prostate cancer
  • Fusion gene ttty15‑usp9y and its application as a marker of prostate cancer
  • Fusion gene ttty15‑usp9y and its application as a marker of prostate cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0097] Summary of clinical specimen information

[0098] In this study, 253 consecutive clinical cases were selected, of which 12 cases were excluded due to poor RNA quantity or quality in urine sediment, and 15 cases were excluded due to insufficient collection of prostate cells in urine sediment. Therefore, the final cases of this study The number is 226 cases. The clinical information of all cases is summarized in Table 1. As can be seen from Table 1, the mean value of serum PSA in all puncture patients was 10.2ng / ml (interquartile range: 7.1-17.7ng / ml), and the puncture Gleason score7 points accounted for 38.6%. In the general population, PCa-related risk factors (age, total PSA, prostate volume, PSA free ratio, and digital rectal examination) and urine fusion gene TTTY15-USP9Y score were significantly higher in the biopsy-positive group than in the biopsy-negative group. In the PSA "diagnostic gray zone" population, the urinary fusion gene TTTY15-USP9Y score in the biop...

Embodiment 2

[0100] The urine fusion gene TTTY15-USP9Y score can clearly distinguish the tumor group from the biopsy-negative group and is highly correlated with the detection rate of PCa

[0101] In order to study whether the urine fusion gene TTTY15-USP9Y score can be used as an effective PCa molecular marker, the inventors of this study detected the urine fusion gene TTTY15-USP9Y score in all puncture-injected populations, and made further statistics academic analysis. The study found that whether in the general population or in the PSA "diagnostic gray area" population, the expression of the urine fusion gene TTTY15-USP9Y score in the biopsy-positive group was significantly higher than that of the biopsy-negative cases, such as figure 2 The differences in the expression of the urine fusion gene TTTY15-USP9Y score in the biopsy-positive group (tumor group) and the biopsy-negative group are shown. 10ng / ml) crowd, the puncture-positive group was significantly higher than the puncture-ne...

Embodiment 3

[0104] Logistic regression analysis of the diagnostic performance of urine MALAT-1 score for PCa

[0105] The inventors established univariate and multivariate logistic regression models, and proved that the urinary fusion gene TTTY15-USP9Y score and other risk factors (age, serum PSA level, prostate volume) are independent predictors of PCa in the general population. The urinary fusion gene TTTY15-USP9Y score is still an independent predictor of PCa in the PSA "diagnostic gray zone", see Table 2 and Figure 4 The area under the receiver operating curve shown was used to analyze the diagnostic efficacy of urine fusion gene TTTY15-USP9Y score and other risk factors in diagnosing PCa.

[0106] In the univariate logistic regression model, there was no significant difference in the diagnostic performance of urine fusion gene TTTY15-USP9Y score for PCa compared with total PSA in the general population, but the combined use of urine fusion gene TTTY15-USP9Y score and PSA had no sign...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a fusion gene TTTY15-USP9Y based on urine and applications of fusion gene as prostate cancer marker and in preparing a chip or a preparation or a kit for detecting prostate cancer.

Description

technical field [0001] The invention belongs to the field of molecular biology, in particular, the invention relates to urine long-chain non-coding TTTY15-USP9Y and its application as a prostate cancer marker. Background technique [0002] Prostate cancer (PCa) is a malignant tumor that seriously threatens men's health. Its morbidity and mortality peak at around 70 years old, accounting for the second highest cancer incidence rate and the sixth highest mortality rate in the world. The incidence of PCa in my country has been on a significant upward trend in recent years. In Beijing, Shanghai, Guangzhou and other medically and economically developed cities, the incidence of PCa has already ranked among the top ten common tumors in the local area. Data from the Shanghai Center for Disease Control further show that the incidence of PCa has leapt to the top of male genitourinary malignant tumors since 2002, rising from 2.6 / 100,000 in 1990 to 32.23 / 100,000 in 2009, ranking first ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/113C12Q1/68C40B40/06
Inventor 孙颖浩任善成朱亚生
Owner SHANGHAI CHANGHAI HOSPITAL